| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2023-092 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | | 浙江华海药业股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第二次临时股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 5 日 至 2023 年 9 月 5 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，1 ...

重要内容提示： 截至 2023 年 8 月 16 日，浙江华海药业股份有限公司（以下简称"公司"） 股价已出现任意三十个连续交易日中至少十五个交易日收盘价格低于当期转股 价格的 80%之情形，触及"华海转债"转股价格向下修正条款。 经公司第八届董事会第十六次临时会议审议通过，公司董事会决议本次不行 使"华海转债"转股价格向下修正的权利，且在未来 2 个月内（2023 年 8 月 17 日至 2023 年 10 月 16 日），如再次触及可转债的转股价格向下修正条款，亦不提 出向下修正方案。从 2023 年 10 月 17 日开始重新起算，若再次触发"华海转债" 的转股价格向下修正条款，届时公司董事会将再次召开会议决定是否行使"华海 转债"的转股价格向下修正权利。 一、可转换公司债券基本情况 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2023-090 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于不向下修正"华海转债"转股价格的公告 本公司董事会及全体董 ...

债券简称：华海转债 债券代码：110076 股票简称：华海药业 股票代码：600521 公告编号：临 2023-088 号 浙江华海药业股份有限公司 第八届董事会第十六次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第八届董事会第十六次临时会议 于二零二三年八月十六日下午十五点以通讯方式在公司四楼会议室召开。会议应到 会董事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司董 事长李宏先生主持。会议程序符合《公司法》及《公司章程》的规定，会议合法有 效。会议审议并通过了如下决议： 二、审议通过了《关于延长公司向特定对象发行股票股东大会决议有效期及授 权有效期的议案》 表决情况：同意：9 票；反对：0 票；弃权：0 票。 会议决议：为顺利推进本次向特定对象发行股票的后续事项，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司证券发行注册管理办法》等现 行法律、法规及规范性文件的规定，董事会同意公司将向特定对象发行股票股东大 会决议有效 ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券发行 注册管理办法》等现行法律、法规及规范性文件的规定，公司向特定对象发行股票 股东大会决议有效期及授权有效期均为一年，因此为顺利推进本次向特定对象发行 股票的后续事宜，公司拟将向特定对象发行股票股东大会决议有效期及授权有效期 延长至 2024 年 9 月 14 日届满。除延长上述有效期外，本次向特定对象发行股票的 债券简称：华海转债 债券代码：110076 浙江华海药业股份有限公司 关于延长公司向特定对象发行股票股东大会 决议有效期及授权有效期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）于 2023 年 8 月 16 日分别召开 了第八届董事会第十六次临时会议、第八届监事会第九次临时会议，会议均审议通 过了《关于延长公司向特定对象发行股票股东大会决议有效期及授权有效期的议 案》，现将相关情况公告如下： 一、关于延长向特定对象发行股票股东大会决议有效期及授权有效期的情况 公司分别于 2022 年 8 月 ...

浙江华海药业股份有限公司 独立董事独立意见 浙江华海药业股份有限公司独立董事 关于第八届董事会第十六次临时会议相关事项的独立意见 根据《上海证券交易所股票上市规则》《浙江华海药业股份有限公司公司章程》 等有关规定，作为浙江华海药业股份有限公司（以下简称"公司"）的独立董事，我 们仔细审阅了公司第八届董事会第十六次临时会议相关资料，经审慎分析，现发表 独立意见如下： 二零二三年八月十六日 1 因此，我们同意延长上述股东大会决议有效期及授权有效期，并同意将该等事 项提交公司股东大会审议。 浙江华海药业股份有限公司 独立董事：李刚、王学恭、辛金国 一、关于延长公司向特定对象发行股票股东大会决议有效期及授权有效期的独 立意见 公司延长本次向特定对象发行股票的股东大会决议有效期和股东大会授权董事 会及董事会授权人士办理本次向特定对象发行股票具体事宜的有效期，有利于保障 公司向特定对象发行股票工作持续、有效、顺利完成。该事项的审议履行了必要的 法律程序，符合有关法律、法规、规章和规范性文件的规定，不存在损害公司和全 体股东特别是中小股东利益的情形。 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2023-089 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 一、审议通过了《关于延长公司向特定对象发行股票股东大会决议有效期 及授权有效期的议案》 表决情况：同意 3 票； 反对 0 票； 弃权 0 票。 会议决议：公司本次延长向特定对象发行股票股东大会决议有效期和股东大 会授权董事会及董事会授权人士办理本次向特定对象发行股票具体事宜的有效 期，有利于保障公司向特定对象发行股票工作的顺利开展，符合有关法律、法规 和《公司章程》的规定，不存在损害公司及股东利益的情形。监事会一致同意公 司将本次向特定对象发行股票的股东大会决议有效期和授权有效期自原届满之 日延长至 2024 年 9 月 14 日。除延长上述有效期外，公司关于本次向特定对象发 行股票的其他内容均保持不变。 浙江华海药业股份有限公司 第八届监事会第九次临时会议决议公告（通讯方式） 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实 ...

股票简称：华海药业 股票代码：600521 公告编号：临 2023-087 号 债券简称：华海转债 债券代码：110076 浙江华海药业股份有限公司 关于"华海转债"预计触发转股价格向下修正的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 规定，"上市公司应当在预计触发转股价格修正条件的 5 个交易日前及时披露提示 性公告。"自 2023 年 7 月 27 日至 2023 年 8 月 9 日，公司股票在连续 30 个交易日 中已有 10 个交易日的收盘价低于当期转股价格的 80%，预计触发转股价格向下修 正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股价 格，并及时履行信息披露义务。 一、可转债上市发行概况 经中国证券监督管理委员会《关于核准浙江华海药业股份有限公司公开发行可 转换公司债券的批复》（证监许可[2020]2261 号）核准，公司于 2020 年 11 月 2 日 公开发行了 1,84 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2023-049 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度经营成果及财 务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投 资者普遍关注的问题进行回答。 1 会议召开时间：2023 年 05 月 12 日（星期五） 下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议主题：沪市主板生物医药行业上市公司集体业绩说明会 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 05 日（星期五）至 05 月 11 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600521@huahaipharm.com 进行提问。公司将在说明 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 2,058,913,113.43, representing a year-on-year increase of 16.15%[4] - The net profit attributable to shareholders of the listed company was RMB 172,934,924.85, up 25.59% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 188,552,713.22, reflecting a 44.34% increase year-on-year[4] - The basic earnings per share for the period was RMB 0.12, representing a 20.00% increase[4] - The weighted average return on equity was 2.26%, an increase of 0.18 percentage points[4] - The net profit for Q1 2023 was CNY 168,505,392.26, an increase of 20.5% compared to CNY 139,878,030.56 in Q1 2022[22] - The total comprehensive income for Q1 2023 was CNY 165,996,029.57, compared to CNY 139,775,078.82 in Q1 2022, an increase of 18.7%[22] - The total profit for Q1 2023 was CNY 177,182,403.86, an increase from CNY 129,224,930.94 in Q1 2022, representing a growth of approximately 37.06%[31] - The net profit for Q1 2023 reached CNY 148,538,126.97, compared to CNY 106,376,314.80 in Q1 2022, marking an increase of about 39.67%[31] Cash Flow - The net cash flow from operating activities was RMB 373,933,429.54, showing a significant increase of 269.74%[4] - The cash flow from operating activities netted CNY 373,933,429.54, significantly higher than CNY 101,134,514.53 in the previous year, marking a growth of 269.5%[24] - Cash flow from operating activities for Q1 2023 was CNY 1,152,043,927.65, significantly up from CNY 540,029,542.11 in Q1 2022, indicating a growth of approximately 113.33%[32] - The total cash inflow from operating activities in Q1 2023 was CNY 2,150,341,175.61, while cash outflow was CNY 998,297,247.96, resulting in a net cash flow of CNY 1,152,043,927.65[32] Assets and Liabilities - Total assets at the end of the reporting period were RMB 18,694,368,161.57, a 2.99% increase from the end of the previous year[5] - The total assets as of March 31, 2023, were CNY 18,694,368,161.57, compared to CNY 18,151,737,482.18 at the end of 2022, reflecting an increase of 3.0%[18] - The total liabilities increased to CNY 10,764,516,339.35 as of March 31, 2023, from CNY 10,406,116,493.24 at the end of 2022, marking a rise of 3.4%[17] - The total liabilities increased to CNY 8,429,117,242.25 in Q1 2023 from CNY 7,944,976,145.97 in Q4 2022, marking an increase of about 6.1%[29] - The company's total assets as of March 31, 2023, amounted to CNY 17,881,973,790.67, an increase from CNY 17,236,575,254.67 at the end of 2022[29] Operating Costs and Expenses - The total operating costs for Q1 2023 were CNY 1,791,603,923.39, up 13.4% from CNY 1,578,705,956.71 in Q1 2022[19] - The total operating expenses for Q1 2023 were CNY 1,915,233,073.00, compared to CNY 1,825,919,831.07 in the previous year, reflecting an increase of 4.9%[24] Research and Development - Research and development expenses for Q1 2023 were CNY 202,193,404.97, slightly down from CNY 217,360,827.03 in Q1 2022[19] - Research and development expenses decreased to CNY 89,062,323.41 in Q1 2023 from CNY 103,942,743.89 in Q1 2022, a reduction of about 14.4%[30] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Other Financial Metrics - The gross profit margin for Q1 2023 was approximately 13.0%, compared to 10.9% in Q1 2022[19] - The gross profit for Q1 2023 was CNY 616,191,891.56, up from CNY 518,773,151.52 in Q1 2022, indicating a gross margin improvement[30] - The company reported a foreign exchange loss of CNY 2,258,971.89 in Q1 2023, compared to a loss of CNY 50,234.73 in Q1 2022[22] Borrowings - The company raised CNY 1,430,000,000.00 through borrowings in Q1 2023, compared to CNY 1,005,085,600.00 in Q1 2022, indicating a growth of 42.2%[24] - The company received CNY 1,010,000,000.00 in cash from borrowings in Q1 2023, a significant increase from CNY 275,000,000.00 in Q1 2022, representing a growth of about 267.27%[32] Cash and Cash Equivalents - The company's cash and cash equivalents increased to CNY 1,728,714,585.72 as of March 31, 2023, from CNY 1,365,152,641.03 at the end of 2022, representing a growth of 26.7%[14] - The cash and cash equivalents at the end of Q1 2023 stood at CNY 1,695,549,488.10, slightly down from CNY 1,720,947,195.78 at the end of Q1 2022[25] - The ending balance of cash and cash equivalents as of Q1 2023 was CNY 953,478,680.20, compared to CNY 587,657,165.25 at the end of Q1 2022, indicating an increase of approximately 62.14%[32]

Financial Performance - The company's operating revenue for 2022 reached ¥8,265,744,793.28, representing a 24.42% increase compared to ¥6,643,573,143.13 in 2021[19]. - Net profit attributable to shareholders for 2022 was ¥1,167,758,749.48, a significant increase of 139.52% from ¥487,535,117.22 in 2021[19]. - The net profit after deducting non-recurring gains and losses was ¥1,153,066,098.54, showing an impressive growth of 1,839.98% compared to ¥59,437,076.89 in 2021[19]. - The weighted average return on equity increased to 16.55% in 2022, up by 9.12 percentage points from 7.43% in 2021[20]. - The company reported a net cash flow from operating activities of ¥1,242,693,126.90, which is a 32.42% increase from ¥938,429,830.68 in 2021[19]. - The total assets at the end of 2022 were ¥18,151,737,482.18, reflecting a 17.35% increase from ¥15,468,124,894.16 at the end of 2021[19]. - Basic earnings per share for 2022 were ¥0.81, a 138.24% increase from ¥0.34 in 2021[20]. - The company achieved a record revenue of 8,265.74 million yuan in 2022, representing a year-on-year growth of 24.42%[27]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, reached 1,153.07 million yuan, a significant increase of 1,839.98% year-on-year[27]. Dividend Distribution - The company plans to distribute a cash dividend of 2.4 CNY per 10 shares, which represents 30.27% of the net profit attributable to ordinary shareholders for 2022[4]. - The total cash dividend amount for 2022 is 353,476,365.12 RMB, which represents 30.27% of the net profit attributable to ordinary shareholders in the consolidated financial statements[191]. - The total dividend amount, including share repurchase, is 403,496,311.07 RMB, accounting for 34.55% of the net profit attributable to ordinary shareholders[191]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm for the fiscal year 2022[3]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[6]. - The company has not violated decision-making procedures for providing guarantees[6]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in its annual report[5]. - The company has not disclosed any significant changes in its registered address or office address during the reporting period[14]. - The company has confirmed that all board members attended the board meeting[3]. - The company has not faced any issues with more than half of the board members being unable to guarantee the authenticity of the annual report[7]. Market and Sales Performance - The company experienced a significant increase in sales volume due to the recovery of the market after the lifting of the FDA ban and the continuous expansion of its domestic formulation business[21]. - The company reported an increase in exchange gains due to the significant rise in the US dollar exchange rate, contributing to the overall profit increase[21]. - The domestic formulation sales maintained rapid growth, with an average annual compound growth rate exceeding 37.9% from 2020 to 2022[29]. - The company successfully won bids for three products in the seventh batch of national centralized procurement, enhancing market share and expanding the number of selected provinces[29]. - In the U.S. market, 31 out of 54 products had market shares ranking in the top three, with five products holding the number one position[28]. - Raw material sales grew by 18.67% year-on-year, with sales covering 106 countries and regions[30]. Research and Development - The company aims to enhance its research and development capabilities, with over 680 master's and doctoral talents currently on staff, covering various therapeutic areas[35]. - The company has established a comprehensive R&D capability covering biopharmaceuticals, chemical innovative drugs, cell therapy, generic drugs, and chemical raw materials, recognized as a national high-tech enterprise and a leader in the domestic pharmaceutical industry[42]. - The company has over 20 projects in its biopharmaceutical pipeline, with 11 projects currently in clinical trials, including a globally innovative dual-target anti-tumor drug project[44]. - The company has established eight major technology platforms, achieving breakthroughs in continuous flow and asymmetric synthesis technologies[32]. - The company invested a total of 120,190.72 million RMB in R&D during the reporting period, focusing on expanding its pipeline in biopharmaceuticals and small molecule new drugs[94]. Corporate Governance - The company adheres to corporate governance standards, ensuring independent operation of its board and committees, and has held 11 board meetings during the reporting period[155]. - The company has implemented a strict insider information registration management system, ensuring compliance with relevant laws and regulations to protect the rights of minority shareholders[157]. - The company’s governance structure complies with relevant laws and regulations, with no significant discrepancies noted in its governance practices[157]. - The company has established a long-term equity incentive mechanism to align employee interests with company development, promoting talent retention and governance improvement[157]. Strategic Initiatives - The company plans to continue expanding its domestic formulation business and capitalize on the recovery of the U.S. market following the FDA ban lift[62]. - The company aims to achieve a sales revenue of approximately 10 billion yuan in 2023, representing a year-on-year growth of about 20.98%[141]. - The company will focus on accelerating new product development and enhancing project management to expedite the market launch of new products[137]. - The company plans to deepen its global marketing system to enhance its competitive position in both international and domestic markets[138]. - The company is committed to improving its corporate governance structure and internal control mechanisms to enhance operational efficiency[146]. Risk Management - The company faces risks in new product development due to high technical difficulty, significant upfront investment, and lengthy approval cycles, which could adversely affect the recovery of initial investments if products fail to pass registration[147]. - The company is exposed to price volatility in raw materials, which could negatively affect financial performance; however, it is enhancing its core competitiveness by increasing the proportion of formulation business sales[151]. - Changes in industry policies could significantly impact market dynamics, operational models, and profitability if the company fails to adapt to regulatory adjustments[150]. Employee and Talent Management - The company has implemented a training program for employees, focusing on enhancing professional knowledge and leadership skills for management personnel[187]. - The company has a strategic approach to employee compensation, aligning with market levels and focusing on high-value positions[186]. - The company has a talent pool of over 100 high-level professionals with overseas backgrounds and 680 master's and doctoral talents, strengthening its R&D capabilities[54]. Environmental and Social Responsibility - The company invested approximately 303.76 million yuan in environmental protection during the reporting period[200]. - The management team emphasized a commitment to sustainability, aiming for a 50% reduction in carbon emissions by 2030[166].